P/E ratio for Theravance Biopharma (TBPH)
P/E ratio as of April 2024 (TTM): 0.8028
According to Theravance Biopharma 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0.802817. At the end of 2022 the company had a P/E ratio of 0.9723.
P/E ratio history for Theravance Biopharma from 2014 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 0.9723 | -125.96% |
| 2021 | -3.75 | -5.57% |
| 2020 | -3.97 | -34.73% |
| 2019 | -6.08 | -5% |
| 2018 | -6.40 | 25.01% |
| 2017 | -5.12 | -31.78% |
| 2016 | -7.50 | 143.94% |
| 2015 | -3.08 | 53.14% |
| 2014 | -2.01 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Corcept Therapeutics
CORT | 25.9 | 3,130.10% | 🇺🇸 USA |
 Collegium Pharmaceutical
COLL | -110 | -13,854.57% | 🇺🇸 USA |
 Catalyst Pharmaceuticals CPRX | 13.5 | 1,586.11% | 🇺🇸 USA |
 Catalent CTLT | -43.4 | -5,502.49% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.